Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106388 | 0.82 | HTR7 (0.48) | P2RX7HTR7 | |
| SCHEMBL9106386 | 0.82 | HTR7 (0.48) | P2RX7HTR7 | |
| SCHEMBL9105409 | 0.79 | P2RX7 (0.44) | HDAC1HDAC8HDAC6HDAC5P2RX7 | |
| SCHEMBL9106277 | 0.79 | P2RX7 (0.44) | HDAC1HDAC8HDAC6HDAC5P2RX7 | |
| SCHEMBL9109215 | 0.77 | CCR1 (0.47) | HDAC1HDAC8HDAC6HDAC5P2RX7 | |
| SCHEMBL9109207 | 0.77 | CCR1 (0.47) | HDAC1HDAC8HDAC6HDAC5P2RX7 | |
| SCHEMBL9108982 | 0.76 | P2RX7 (0.43) | HDAC1HDAC8HDAC6P2RX7TDP1 | |
| SCHEMBL9108987 | 0.76 | P2RX7 (0.43) | HDAC1HDAC8HDAC6P2RX7TDP1 | |
| SCHEMBL9106829 | 0.75 | HTR7 (0.47) | TDP1HPGDHTR7L3MBTL1 | |
| SCHEMBL9106827 | 0.75 | HTR7 (0.47) | TDP1HPGDHTR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HDAC1 1767/4885HDAC8 2405/4885HDAC6 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.